indv-2000
Small moleculeexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 30, 2020 (NCT04413552)
Timeline
Indications
Mechanism of action
- Orexin receptorANTAGONIST
Orexin receptor antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06384157 | Phase 2 | Jun 10, 2024 | Indivior Inc. |
| NCT05694533 | Phase 1 | Mar 15, 2023 | Celerion, Indivior Inc. |
| NCT04976855 | Phase 1 | Aug 12, 2022 | Altasciences Company Inc., Indivior Inc. |
| NCT04413552 | Phase 1 | Jun 30, 2020 | Altasciences Company Inc., Indivior Inc., National Institute on Drug Abuse (NIDA) |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Indivior Inc. | For profit | 4 | 4 | 2 | 2020 |
| Altasciences Company Inc. | For profit | 2 | 0 | 1 | 2020 |
| Celerion | For profit | 1 | 0 | 1 | 2023 |
| National Institute on Drug Abuse (NIDA) | Government | 1 | 0 | 1 | 2020 |
4 organizations
Page 1 / 1